AllianceBernstein’s Blueprint Medicines BPMC Stock Holding History

AllianceBernstein’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-765,387	Closed	-$98.1M	–	3248
2025 Q2	$98.1M	Sell	765,387 -430,853	-36%	-$44.8M	0.03%	389
2025 Q1	$106M	Buy	1,196,240 +58,218	+5%	+$5.68M	0.04%	348
2024 Q4	$99.3M	Sell	1,138,022 -79,683	-7%	-$7.3M	0.03%	407
2024 Q3	$113M	Buy	1,217,705 +78,703	+7%	+$7.82M	0.04%	370
2024 Q2	$123M	Sell	1,139,002 -64,590	-5%	-$6.47M	0.04%	333
2024 Q1	$114M	Sell	1,203,592 -154,391	-11%	-$13.2M	0.04%	371
2023 Q4	$125M	Sell	1,357,983 -139,271	-9%	-$9.02M	0.05%	335
2023 Q3	$75.2M	Sell	1,497,254 -113,927	-7%	-$6.09M	0.03%	462
2023 Q2	$102M	Sell	1,611,181 -130,623	-7%	-$7.1M	0.04%	389
2023 Q1	$78.4M	Buy	1,741,804 +205,649	+13%	+$9.26M	0.03%	447
2022 Q4	$67.3M	Buy	1,536,155 +127,048	+9%	+$6.09M	0.03%	489
2022 Q3	$92.8M	Sell	1,409,107 -88,298	-6%	-$5.67M	0.05%	376
2022 Q2	$75.6M	Sell	1,497,405 -13,586	-0.9%	-$796K	0.03%	440
2022 Q1	$96.5M	Buy	1,510,991 +10,246	+0.7%	+$735K	0.04%	417
2021 Q4	$161M	Buy	1,500,745 +106,541	+8%	+$11.1M	0.06%	312
2021 Q3	$143M	Sell	1,394,204 -8,035	-0.6%	-$748K	0.06%	322
2021 Q2	$123M	Buy	1,402,239 +2,870	+0.2%	+$263K	0.05%	364
2021 Q1	$136M	Buy	1,399,369 +110,564	+9%	+$11M	0.06%	310
2020 Q4	$145M	Sell	1,288,805 -34,008	-3%	-$3.58M	0.07%	267
2020 Q3	$123M	Buy	1,322,813 +151,989	+13%	+$11.7M	0.07%	267
2020 Q2	$91.3M	Buy	1,170,824 +85,477	+8%	+$5.78M	0.05%	335
2020 Q1	$63.5M	Sell	1,085,347 -39,126	-3%	-$2.52M	0.05%	376
2019 Q4	$90.1M	Buy	1,124,473 +61,955	+6%	+$4.64M	0.05%	356
2019 Q3	$78.1M	Buy	1,062,518 +21,148	+2%	+$1.83M	0.05%	380
2019 Q2	$98.2M	Buy	1,041,370 +49,241	+5%	+$4.06M	0.06%	311
2019 Q1	$79.4M	Buy	992,129 +123,259	+14%	+$9.11M	0.05%	368
2018 Q4	$46.8M	Sell	868,870 -157,952	-15%	-$9.6M	0.03%	493
2018 Q3	$80.2M	Buy	1,026,822 +252,028	+33%	+$17.5M	0.05%	371
2018 Q2	$49.2M	Sell	774,794 -31,733	-4%	-$2.53M	0.03%	511
2018 Q1	$74M	Sell	806,527 -63,240	-7%	-$5.45M	0.05%	376
2017 Q4	$65.6M	Sell	869,767 -204,296	-19%	-$14.4M	0.05%	424
2017 Q3	$74.8M	Sell	1,074,063 -566	-0.1%	-$30.2K	0.06%	375
2017 Q2	$54.5M	Buy	1,074,629 +101,930	+10%	+$4.33M	0.04%	463
2017 Q1	$38.9M	Buy	972,699 +945,999	+3,543%	+$33.9M	0.03%	532
2016 Q4	$749K	Hold	26,700	–	–	﹤0.01%	2404
2016 Q3	$793K	Buy	26,700 +8,600	+48%	+$214K	﹤0.01%	2329
2016 Q2	$367K	Buy	18,100 +1,700	+10%	+$30.9K	﹤0.01%	2627
2016 Q1	$296K	Sell	16,400 -4,200	-20%	-$72.9K	﹤0.01%	2598
2015 Q4	$543K	Buy	20,600 +5,200	+34%	+$117K	﹤0.01%	2414
2015 Q3	$329K	Buy	15,400 +1,100	+8%	+$30.4K	﹤0.01%	2634
2015 Q2	$379K	Buy	+14,300	New	+$408K	﹤0.01%	2686

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AllianceBernstein's BPMC Position: Q3 2025 in Review

AllianceBernstein sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 765,387 shares — an estimated $98.1M sold.

AllianceBernstein first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $161M in Q4 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

AllianceBernstein reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
AllianceBernstein sold 765,387 Blueprint Medicines shares in Q3 2025, an estimated $98.1M.
AllianceBernstein first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
AllianceBernstein's Blueprint Medicines position peaked at $161M in Q4 2021.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on AllianceBernstein's 13F filing for Q3 2025, filed 14 Nov 2025.